AstraZeneca PLC $AZN Shares Sold by Coastline Trust Co

Coastline Trust Co reduced its position in AstraZeneca PLC (NASDAQ:AZN) by 9.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,570 shares of the company’s stock after selling 750 shares during the quarter. Coastline Trust Co’s holdings in AstraZeneca were worth $529,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of AZN. Dynamic Advisor Solutions LLC grew its position in AstraZeneca by 58.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company’s stock worth $960,000 after purchasing an additional 4,811 shares during the last quarter. SCS Capital Management LLC acquired a new stake in shares of AstraZeneca during the first quarter worth about $3,066,000. Farther Finance Advisors LLC grew its holdings in shares of AstraZeneca by 13.1% during the first quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company’s stock worth $442,000 after buying an additional 706 shares during the last quarter. Oliver Luxxe Assets LLC increased its position in AstraZeneca by 6.0% in the 2nd quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company’s stock valued at $5,472,000 after acquiring an additional 4,449 shares during the period. Finally, Alhambra Investment Management LLC purchased a new stake in AstraZeneca during the 2nd quarter valued at approximately $320,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank set a $97.00 price objective on AstraZeneca in a research report on Wednesday, July 9th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Stock Up 0.3%

Shares of NASDAQ:AZN opened at $73.76 on Friday. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $82.41. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The firm’s 50-day simple moving average is $77.13 and its 200-day simple moving average is $72.94. The company has a market cap of $228.76 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 1.36 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. During the same quarter last year, the firm earned $1.24 earnings per share. The firm’s revenue was up 16.1% compared to the same quarter last year. As a group, equities research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were issued a dividend of $0.505 per share. This represents a yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca’s dividend payout ratio is currently 37.97%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.